靶向M细胞的口服疫苗递送系统的研究进展

刘安泽; 董颖心; 王欢; 鲁莹; 刘安泽; 董颖心; 王欢; 鲁莹

doi:10.12206/j.issn.2097-2024.202509037

[1]

SHATTOCK A J, JOHNSON H C, SIM S Y, et al. Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization[J]. Lancet, 2024, 403(10441): 2307-2316. doi: 10.1016/S0140-6736(24)00850-X

[2]

PARKER E P, MOLODECKY N A, PONS-SALORT M, et al. Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame[J]. Expert Rev Vaccines, 2015, 14(8): 1113-1123. doi: 10.1586/14760584.2015.1052800

[3]

LAVELLE E C, WARD R W. Mucosal vaccines: fortifying the frontiers[J]. Nat Rev Immunol, 2022, 22(4): 236-250. doi: 10.1038/s41577-021-00583-2

[4]

ISLAM M A, FIRDOUS J, BADRUDDOZA A Z M, et al. M cell targeting engineered biomaterials for effective vaccination[J]. Biomaterials, 2019, 192: 75-94. doi: 10.1016/j.biomaterials.2018.10.041

[5]

DU G S, QIN M, SUN X. Recent progress in application of nanovaccines for enhancing mucosal immune responses[J]. Acta Pharm Sin B, 2023, 13(6): 2334-2345. doi: 10.1016/j.apsb.2022.08.010

[6]

MABBOTT N A, DONALDSON D S, OHNO H, et al. Microfold(M)cells: important immunosurveillance posts in the intestinal epithelium[J]. Mucosal Immunol, 2013, 6(4): 666-677.

[7]

ZHOU X X, WU Y C, ZHU Z P, et al. Mucosal immune response in biology, disease prevention and treatment[J]. Signal Transduct Target Ther, 2025, 10(1): 7. doi: 10.1038/s41392-024-02043-4

[8]

KUNISAWA J, KURASHIMA Y, KIYONO H. Gut-associated lymphoid tissues for the development of oral vaccines[J]. Adv Drug Deliv Rev, 2012, 64(6): 523-530. doi: 10.1016/j.addr.2011.07.003

[9]

LELOUARD H, FALLET M, DE BOVIS B, et al. Peyer’s patch dendritic cells sample antigens by extending dendrites through M cell-specific transcellular pores[J]. Gastroenterology, 2012, 142(3): 592-601. e3.

[10]

XU Y N, SHRESTHA N, PRÉAT V, et al. Overcoming the intestinal barrier: a look into targeting approaches for improved oral drug delivery systems[J]. J Control Release, 2020, 322: 486-508. doi: 10.1016/j.jconrel.2020.04.006

[11]

DES RIEUX A, RAGNARSSON E G E, GULLBERG E, et al. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium[J]. Eur J Pharm Sci, 2005, 25(4-5): 455-465. doi: 10.1016/j.ejps.2005.04.015

[12]

XU Z J, ZHOU H Y, LI T F, et al. Application of biomimetic nanovaccines in cancer immunotherapy: a useful strategy to help combat immunotherapy resistance[J]. Drug Resist Updat, 2024, 75: 101098. doi: 10.1016/j.drup.2024.101098

[13]

ZHANG Y D, LI M, DU G S, et al. Advancedoral vaccine delivery strategies for improving the immunity[J]. Adv Drug Deliv Rev, 2021, 177: 113928. doi: 10.1016/j.addr.2021.113928

[14]

14] MIAO Y B, LIN Y J, CHEN K H, et al. Engineering nano- and microparticles as oral delivery vehicles to promote intestinal lymphatic drug transport[J]. Adv Mater, 2021, 33(51): e2104139. doi: 10.1002/adma.202104139

[15]

KANG S H, HONG S J, LEE Y K, et al. Oral vaccine delivery for intestinal immunity-biological basis, barriers, delivery system, and M cell targeting[J]. Polymers, 2018, 10(9): 948. doi: 10.3390/polym10090948

[16]

16] LONGET S, LUNDAHL M L E, LAVELLE E C. Targeted strategies for mucosal vaccination[J]. Bioconjug Chem, 2018, 29(3): 613-623. doi: 10.1021/acs.bioconjchem.7b00738

[17]

CLARK M A, BLAIR H, LIANG L, et al. Targeting polymerised liposome vaccine carriers to intestinal M cells[J]. Vaccine, 2001, 20(1-2): 208-217. doi: 10.1016/S0264-410X(01)00258-4

[18]

YEBOAH K G, AKANDE J, ADDO R T, et al. In vitro and ex vivo characterization of lectin-labeled Mycobacterium tuberculosis antigen-containing microspheres for enhanced oral delivery[J]. J Drug Target, 2014, 22(1): 34-47. doi: 10.3109/1061186X.2013.833206

[19]

DES RIEUX A, POURCELLE V, CANI P D, et al. Targeted nanoparticles with novel non-peptidic ligands for oral delivery[J]. Adv Drug Deliv Rev, 2013, 65(6): 833-844. doi: 10.1016/j.addr.2013.01.002

[20]

HASE K, KAWANO K, NOCHI T, et al. Uptake through glycoprotein 2 of FimH(+)bacteria by M cells initiates mucosal immune response[J]. Nature, 2009, 462(7270): 226-230. doi: 10.1038/nature08529

[21]

LING J, LIAO H L, CLARK R, et al. Structural constraints for the binding of short peptides to claudin-4 revealed by surface plasmon resonance[J]. J Biol Chem, 2008, 283(45): 30585-30595. doi: 10.1074/jbc.M803548200

[22]

KIM S H, YANG I Y, JANG S H, et al. C5a receptor-targeting ligand-mediated delivery of dengue virus antigen to M cells evokes antigen-specific systemic and mucosal immune responses in oral immunization[J]. Microbes Infect, 2013, 15(13): 895-902. doi: 10.1016/j.micinf.2013.07.006

[23]

AKASHI S, SAITOH S I, WAKABAYASHI Y, et al. Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14[J]. J Exp Med, 2003, 198(7): 1035-1042.

[24]

CLARK M A, HIRST B H, JEPSON M A. M-cell surface beta1 integrin expression and invasin-mediated targeting of Yersinia pseudotuberculosis to mouse Peyer’s patch M cells[J]. Infect Immun, 1998, 66(3): 1237-1243. doi: 10.1128/IAI.66.3.1237-1243.1998

[25]

MIAO Y B, CHEN K H, CHEN C T, et al. A noninvasive gut-to-brain oral drug delivery system for treating brain tumors[J]. Adv Mater, 2021, 33(34): e2100701. doi: 10.1002/adma.202100701

[26]

WU Y P, WANG X H, CSENCSITS K L, et al. M cell-targeted DNA vaccination[J]. Proc Natl Acad Sci U S A, 2001, 98(16): 9318-9323. doi: 10.1073/pnas.161204098

[27]

HUMPHRIES J D, BYRON A, HUMPHRIES M J. Integrin ligands at a glance[J]. J Cell Sci, 2006, 119(Pt 19): 3901-3903.

[28]

KIM S H, JUNG D I, YANG I Y, et al. Application of an M-cell-targeting ligand for oral vaccination induces efficient systemic and mucosal immune responses against a viral antigen[J]. Int Immunol, 2013, 25(11): 623-632. doi: 10.1093/intimm/dxt029

[29]

YOO M K, KANG S K, CHOI J H, et al. Targeted delivery of chitosan nanoparticles to Peyer’s patch using M cell-homing peptide selected by phage display technique[J]. Biomaterials, 2010, 31(30): 7738-7747. doi: 10.1016/j.biomaterials.2010.06.059

[30]

LI W Q, YANG X, WANG M F, et al. Development of a cascade-targeting oral vaccine via glycoprotein 2 on intestinal microfold cells for cancer immunotherapy[J]. Nano Lett, 2025, 25(13): 5165-5173. doi: 10.1021/acs.nanolett.4c06123

[31]

NOCHI T, YUKI Y, MATSUMURA A, et al. A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses[J]. J Exp Med, 2007, 204(12): 2789-2796. doi: 10.1084/jem.20070607

[32]

SHIMA H, WATANABE T, FUKUDA S, et al. A novel mucosal vaccine targeting Peyer’s patch M cells induces protective antigen-specific IgA responses[J]. Int Immunol, 2014, 26(11): 619-625. doi: 10.1093/intimm/dxu061

[33]

ROCHEREAU N, PAVOT V, VERRIER B, et al. Delivery of antigen to nasal-associated lymphoid tissue microfold cells through secretory IgA targeting local dendritic cells confers protective immunity[J]. J Allergy Clin Immunol, 2016, 137(1): 214-222. e2.

[34]

ROCHEREAU N, MICHAUD E, WAECKEL L, et al. Essential role of TOSO/FAIM3 in intestinal IgM reverse transcytosis[J]. Cell Rep, 2021, 37(7): 110006. doi: 10.1016/j.celrep.2021.110006

[35]

KUMAR R, DKHAR D S, KUMARI R, et al. Lipid based nanocarriers: Production techniques, concepts, and commercialization aspect[J]. J Drug Deliv Sci Technol, 2022, 74: 103526. doi: 10.1016/j.jddst.2022.103526

[36]

周娇, 郑建雨, 王思真, 等. mRNA肿瘤疫苗非病毒递送系统研究进展[J]. 药学实践与服务, 2025, 43(3): 109-116.

[37]

陈昕璐, 高原, 李鹃鹃, 等. mRNA脂质纳米粒载药系统的构建及体外评价[J]. 药学实践与服务, 2023, 41(5): 291-295. doi: 10.12206/j.issn.2097-2024.202302026

[38]

刘安泽, 何盈盈, 王欢, 等. 基于天然IgM新型佐剂的叶酸脂质体疫苗制备及评价[J]. 药学实践与服务, 2025, 43(11): 555-559.

[39]

LUO P K, CHANG W N, PENG S Y, et al. Endogenous macrophages as “Trojan horses” for targeted oral delivery of mRNA-encoded cytokines in tumor microenvironment immunotherapy[J]. Biomaterials, 2026, 325: 123620. doi: 10.1016/j.biomaterials.2025.123620

[40]

XIN X F, WU D, ZHAO P B, et al. Catch-to-amplify nanoparticles with bacteria surface for sequential mucosal immune activation for acute myeloid leukemia therapy[J]. ACS Nano, 2025, 19(15): 14661-14679. doi: 10.1021/acsnano.4c08515

[41]

NGUYEN N, HOANG T M, HUANG T, et al. Macrophage-hitchhiked, effervescence-induced nanoemulsions for enhanced oral chemotherapy and immunotherapy: Impact on absorption route[J]. Biomaterials, 2025, 316: 123019. doi: 10.1016/j.biomaterials.2024.123019

[42]

WANG C F, TANG H B, DUAN Y F, et al. Oral biomimetic virus vaccine hydrogel for robust abscopal antitumour efficacy[J]. J Colloid Interface Sci, 2024, 674: 92-107. doi: 10.1016/j.jcis.2024.06.102

[43]

CHEN K H, NGUYEN N, HUANG T, et al. Macrophage-hitchhiked orally administered β-glucans-functionalized nanoparticles as “precision-guided stealth missiles” for targeted pancreatic cancer therapy[J]. Adv Mater, 2023, 35(40): e2304735. doi: 10.1002/adma.202304735

[44]

NGUYEN V K, NGUYEN N, LI Z C, et al. Inflammation-activated endogenous macrophage-mediated prodrug delivery system overcoming biological barriers for enhanced oral meningitis therapy[J]. Adv Funct Mater, 2024, 34(32): 2401570. doi: 10.1002/adfm.202401570

[45]

CHEN D Y, LIU X C, LU X Y, et al. Nanoparticle drug delivery systems for synergistic delivery of tumor therapy[J]. Front Pharmacol, 2023, 14: 1111991. doi: 10.3389/fphar.2023.1111991

[46]

GUO W, WANG Z Q, XUE R B, et al. The minimalist epigenetic nano-adjuvant gMSN reprograms dendritic cells to enhance the mucosal immune response of oral vaccines[J]. Biomaterials, 2026, 324: 123459. doi: 10.1016/j.biomaterials.2025.123459

[47]

SIBORO P Y, NGUYEN N, LO S K, et al. Innate immunity-guided macrophage-homing nanoplatform for oral tumor immunotherapy and real-time deep-tissue imaging in pre-clinical models[J]. Adv Mater, 2025, 37(40): e07607. doi: 10.1002/adma.202507607

[48]

CHEN Z, QIN Y T, LI Q R, et al. Layer-by-layer deposition of antigen peptides on Bifidobacterium for subintestinal lymphatic system-guided personalized tumor immunotherapy[J]. Adv Mater, 2025, 37(26): e2503571. doi: 10.1002/adma.202503571

[49]

CHEN X N, SHI T F, CHEN F M, et al. Orally antigen-engineered yeast vaccine elicits robust intestinal mucosal immunity[J]. ACS Nano, 2025, 19(11): 10841-10853. doi: 10.1021/acsnano.4c14690

[50]

LI J X, YANG R Q, YUAN Y H, et al. An oral nanovaccine secreted by genetically engineered and ultrasound-responsive bacteria for colon cancer immunotherapy[J]. Adv Funct Mater, 2025, 35(6): 2414994. doi: 10.1002/adfm.202414994